8-K: Protagenic Therapeutics Secures Key Patent in Japan for Epilepsy Drug Program

Protagenic Therapeutics, Inc. announced the grant of a new patent in Japan for its modified stilbenoid program drug candidates, providing exclusivity for compounds and their medical use in treating epilepsy and seizures.

Summary

• Protagenic Therapeutics, Inc. (Nasdaq: PTIX) was granted Patent JP 7714571B by the Japanese Patent Office on July 18, 2025.
• The patent is valid until March 31, 2041.
• It covers modified stilbenoid drug candidates, providing exclusivity for particular compounds, formulations, and their medical use in treating epilepsy and seizures.
• This patent builds on a previous grant of the same patent in the UK (Patent GB2609814).

Sentiment

Score: 8

Explanation: The grant of a key patent in a major market for a significant drug program is a strong positive development, enhancing the company's intellectual property and future revenue potential. The long patent life and large target markets contribute to a high positive sentiment.

Positives

• Secured a new patent (JP 7714571B) in Japan, a significant pharmaceutical market.
• Patent provides exclusivity for key pipeline assets, including specific compounds, formulations, and their medical use for epilepsy and seizures.
• The patent extends until March 31, 2041, offering long-term protection.
• Builds on a previously granted patent in the UK (GB2609814), demonstrating consistent innovation.
• The Japanese pharmaceutical market is the world's third largest, valued at over $85 billion USD in 2025, projected to reach $93 billion USD by 2030.
• The global epilepsy drug market was valued at $11.29 billion USD in 2024 and is anticipated to reach $18.74 billion USD by 2034, growing at a CAGR of 5.20%.

Risks

• Forward-looking statements are subject to substantial risks and uncertainties.
• Inherent uncertainties, risks, and assumptions are difficult to predict.
• Risks related to the completion, timing, and results of current and future clinical studies relating to the Company's product candidates.
• Assumptions as to future events may not prove to be accurate.
• Other risks and uncertainties are described more fully in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

The Company anticipates being able to expand the grant of this patent in other territories in the future. Forward-looking statements are subject to risks and uncertainties, including those related to clinical study completion, timing, and results.

Management Comments

• "We are delighted to announce the grant of this important patent for the Company in Japan."
• "Such a grant builds on the previous grant of the same patent in the UK (Patent GB2609814), and demonstrates the ability of the Company to continue its innovative approach and to add value and important protection to its development pipeline for shareholders."
• "We anticipate being able to expand the grant of this patent in other territories in the future."

Industry Context

The patent grant positions Protagenic Therapeutics to potentially capitalize on the significant Japanese pharmaceutical market, which is the world's third largest, and the growing global epilepsy drug market. This strategic intellectual property protection is crucial for drug development companies operating in competitive therapeutic areas.

Comparison to Industry Standards

• The filing highlights the Japanese pharmaceutical market's size ($85 billion USD in 2025, projected to $93 billion USD by 2030) and the global epilepsy drug market's growth ($11.29 billion USD in 2024 to $18.74 billion USD by 2034 at a 5.20% CAGR). These figures provide context for the market opportunity but do not offer specific comparable company or project results.
• The patent grant itself is a standard and critical milestone for pharmaceutical companies, aligning with industry best practices for protecting novel drug candidates.

Stakeholder Impact

• Shareholders: Increased value and protection for the development pipeline, potentially leading to higher share price due to enhanced intellectual property and market access.
• Patients (Epilepsy/Seizure): Potential for new treatment options if the drug candidates successfully complete clinical development.

Next Steps

• Expand the patent grant to other territories in the future.
• Continue with current and future clinical studies relating to the Company's product candidates.

Key Dates

Recommendation

The grant of a significant patent in Japan for a key drug candidate targeting epilepsy and seizures represents a substantial de-risking event and a strong positive catalyst. This intellectual property protection in the world's third-largest pharmaceutical market, coupled with the long patent life until 2041, significantly enhances the company's long-term value proposition and competitive moat. The potential to expand this patent to other territories further strengthens the outlook. Given the large and growing target markets for epilepsy drugs, this patent positions Protagenic Therapeutics for future growth and profitability, making it an attractive investment.

Keywords

Protagenic Therapeutics, PTIX, Patent, Japan, Epilepsy, Seizures, Stilbenoid, Drug Candidates, Pharmaceutical Market, Biotechnology, Intellectual Property